Detection of Chemotherapy Induced Cardiotoxicity

Detection of Chemotherapy Induced Cardiotoxicity

To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).

To identify patients at risk of development of heart damage after receiving chemotherapy by obtaining the genetic profile of those who show: elevation of troponin, left ventricular systolic and diastolic dysfunction, and pro-oxidant stress markers.

Inclusion Criteria:

• undergoing anthracycline and/or trastuzumab therapy for the first time

Exclusion Criteria:

• abnormal ventricular ejection fraction
• past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension